Targeted therapies are rationally designed to interfere with specific molecular events that
are important in tumour growth, progression or survival. Several targeted therapies with anti …

Small molecule tyrosine kinase inhibitors (TKIs) are developed to block intracellular
signaling pathways in tumor cells, leading to deregulation of key cell functions such as …

Abstract Treatment of second-and third-line patients with non–small-cell lung carcinoma
(NSCLC) with the epidermal growth factor receptor (EGFR) kinase inhibitor erlotinib …

Cancers with specific genetic mutations are susceptible to selective kinase inhibitors.
However, there is a wide spectrum of benefit among cancers harboring the same sensitizing …

The metastatic process involves the migration and invasion of cancer cells throughout the
body to produce secondary tumors at distant sites. Through of epithelial-mesenchymal …

Epidermal growth factor receptor (EGFR) plays critical roles in many biological processes
and in tumorigenesis. Here, we show that two mutated EGFRs found in lung and other …

Purpose. To characterize the chemotherapy given near the end of life to advanced non-
small cell lung cancer (NSCLC) patients treated in the community oncology setting using a …

Non-small cell lung cancer (NSCLC) inevitably develops resistance to epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment. In 5–20% of cases, this can …

Lung cancer first line treatment has been directed from the non-specific cytotoxic doublet
chemotherapy to the molecular targeted. The major limitation of the targeted therapies still …

The CME activity for this article is forthcoming. Access and take the CME test online and
receive 1 hour of AMA PRA category 1 credit at CME. TheOncologist. com Gefitinib (Iressa®; …